Surgical Oncology-Oxford最新文献

{"title":"Impact of age on surgical excision margins for vulvar squamous cell carcinomas: A multicenter study by the francogyn group","authors":"E. Raimond ,&nbsp;C. Ambroise ,&nbsp;Y. Kerbage ,&nbsp;L. Ouldamer ,&nbsp;S. Bendifallah ,&nbsp;X. Carcopino ,&nbsp;M. Koskas ,&nbsp;P.A. Bolze ,&nbsp;V. Lavoué ,&nbsp;T. Gauthier ,&nbsp;O. Graesslin ,&nbsp;A. Fauconnier ,&nbsp;C. Huchon ,&nbsp;Francogyn Group","doi":"10.1016/j.suronc.2024.102170","DOIUrl":"10.1016/j.suronc.2024.102170","url":null,"abstract":"<div><h3>Introduction</h3><div>Vulvar cancer is a rare cancer, it most often affects older women, with tumours of more advanced size and stage than in younger patients. The first-line treatment for vulvar cancer is surgery. Current European and American guidelines recommend negative histological margins. As tumor size is greater in older patients, the aim of this study was to assess the impact of patient age on surgical excision margins in squamous cell carcinomas of the vulva.</div></div><div><h3>Material and method</h3><div>This was a retrospective multicenter observational study. A descriptive analysis of the population was performed and a univariate analysis was performed according to patient age. Survival data were plotted using the Kaplan-Meier method and compared using a log rank test. Survival was analyzed using a Cox model to calculate the Hazard Ratio.</div></div><div><h3>Results</h3><div>Among the 547 patients included, there were 206 patients &lt;65 years and 341 ≥ 65 years, including 135 ≥ 80 years. Median postoperative histological lesion size and interquartile range was greater in patients ≥65 years (30 mm [18–45] versus 26 mm [14–34], p &lt; 0.001). Patients ≥65 years of age more often benefited from radical total vulvectomy (n = 103 (28.8 %) versus n = 44 (20.4 %), p = 0.03). However, negative surgical excision margins were identical between the 2 groups (n = 180 (87.4 %) versus n = 286 (83.9 %), p = 0.21). Revision surgery was performed more frequently in patients &lt;65 years. Recurrence-free survival was better in patients aged &lt;65 years (HR = 0.60; CI95 % (0.45–0.82), p = 0.001).</div></div><div><h3>Conclusion</h3><div>Despite larger tumour size, age is not a factor influencing the achievement of negative excision margins in squamous cell carcinomas of the vulva, at the cost of more radical surgery.</div></div>","PeriodicalId":51185,"journal":{"name":"Surgical Oncology-Oxford","volume":"58 ","pages":"Article 102170"},"PeriodicalIF":2.3,"publicationDate":"2024-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142755811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The potential of AI-assisted gastrectomy with dual highlighting of pancreas and connective tissue","authors":"Tatsuro Nakamura,&nbsp;Yasunori Kurahashi,&nbsp;Yoshinori Ishida,&nbsp;Hisashi Shinohara","doi":"10.1016/j.suronc.2024.102171","DOIUrl":"10.1016/j.suronc.2024.102171","url":null,"abstract":"<div><h3>Background</h3><div>Standard gastrectomy with D2 lymph node (LN) dissection for gastric cancer involves peripancreatic lymphadenectomy [<span><span>1</span></span>]. This technically demanding procedure requires meticulous dissection within the dissectable layers of connective tissue, while identifying and preserving the pancreas [<span><span>2</span></span>]. Our previous study demonstrated the proficiency of Eureka, a surgical artificial intelligence (AI) system, in recognizing both connective tissue and the pancreas [<span><span>3</span></span>,<span><span>4</span></span>]. Dual highlighting of these structures is expected to reduce surgeon stress by aiding in anatomical identification, thereby ensuring safer and more accurate surgery.</div></div><div><h3>Methods</h3><div>Connective tissue and the pancreas were highlighted by the surgical AI system in surgical videos on no. 6 (infrapyloric LNs), no. 8 (LNs along the common hepatic artery), and no. 13 (LNs on the posterior surface of the pancreatic head) dissection. These videos were specifically selected as surgeons encountered difficulty in distinguishing the dissectable layers and the pancreatic process.</div></div><div><h3>Results</h3><div>All videos showed variations of pancreatic morphologies that differed in size and shape. The AI system consistently highlighted the pancreatic process even during initial exploration. Furthermore, it recognized connective tissue, which delineated the appropriate layers for dissection.</div></div><div><h3>Conclusions</h3><div>The surgical AI system accurately demonstrated dual highlighting of the pancreatic process and connective tissues. Although there are challenges for clinical application, this system can be a valuable tool for anatomical guidance and recognition during surgery, potentially leading to safer and better outcomes.</div></div>","PeriodicalId":51185,"journal":{"name":"Surgical Oncology-Oxford","volume":"58 ","pages":"Article 102171"},"PeriodicalIF":2.3,"publicationDate":"2024-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142757579","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Laparoscopic subsegmentectomy 5 for deeply located hepatocellular carcinoma surrounded by major portal pedicles and middle hepatic vein","authors":"Ji Hoon Kim","doi":"10.1016/j.suronc.2024.102166","DOIUrl":"10.1016/j.suronc.2024.102166","url":null,"abstract":"","PeriodicalId":51185,"journal":{"name":"Surgical Oncology-Oxford","volume":"57 ","pages":"Article 102166"},"PeriodicalIF":2.3,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142696174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ICG-guided sentinel lymph node biopsy in melanoma is as effective as blue dye: A retrospective analysis","authors":"Danielle Lavy ,&nbsp;Michal Shimonovitz ,&nbsp;Daniel Keidar ,&nbsp;Anton Warshavsky ,&nbsp;Yonatan Lessing ,&nbsp;Adam Abu-Abeid ,&nbsp;Schlomo Schneebaum ,&nbsp;Mor Miodovnik ,&nbsp;Eran Nizri","doi":"10.1016/j.suronc.2024.102167","DOIUrl":"10.1016/j.suronc.2024.102167","url":null,"abstract":"<div><h3>Introduction</h3><div>Sentinel lymph node biopsy (SLNB) is a key procedure in the staging and management of melanoma. Traditionally, it is performed using a dual-mapping technique combining a radioactive isotope (RI) and blue dye (BD). Fluorescence-guided surgery with indocyanine green (ICG) has emerged as an alternative tracer, offering potential advantages in real-time visualization and operative efficiency. This study compares the efficacy of RI + ICG with RI + BD in SLNB for melanoma.</div></div><div><h3>Methods</h3><div>We conducted a retrospective cohort study at a single center, including 311 patients who underwent SLNB for melanoma. Patients were divided into two groups: RI + BD (n = 227, January 2010–August 2022) and RI + ICG (n = 84, August 2022–February 2024). SLN detection rates, positive SLN rates, operative times, and postoperative complications were compared between the two groups.</div></div><div><h3>Results</h3><div>Both groups were clinically and pathologically comparable. SLN detection rates were 100 % in the RI + BD group and 98.8 % in the RI + ICG group (p = 0.1). The median number of lymph nodes resected was lower in the RI + ICG group as compared to the RI + BD group (p = 0.047). While positive SLN rates were higher in the RI + ICG group (9.5 % vs. 6.2 %), this difference was not statistically significant (p = 0.3). ICG alone could not identify all the positive SLN. Postoperative complications, including seroma, did not differ significantly between groups.</div></div><div><h3>Conclusions</h3><div>ICG-guided SLNB is comparable to BD-guided SLNB in terms of detection rate and SLN positivity, although it can not be used alone to identify all positive SLNBs. ICG-based fluorescence imaging is a promising technique that may enhance surgical efficiency in melanoma management.</div></div>","PeriodicalId":51185,"journal":{"name":"Surgical Oncology-Oxford","volume":"57 ","pages":"Article 102167"},"PeriodicalIF":2.3,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142707080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"T-cell immunotherapy for melanoma","authors":"Cristian Mantilla Rosa ,&nbsp;Aparna Vancheswaran ,&nbsp;Charlotte E. Ariyan","doi":"10.1016/j.suronc.2024.102160","DOIUrl":"10.1016/j.suronc.2024.102160","url":null,"abstract":"<div><div>This review explores T-cell immunotherapy for melanoma, highlighting immune checkpoint inhibitors (anti-CTLA-4, anti-PD-1, anti-LAG-3), tumor-infiltrating lymphocytes (TILs), and emerging therapies that engineer T cells with specific receptors or T-cell receptors, such as CAR-T and TCR cells, and RNA vaccines. We discuss the history of T-cell immunotherapy, mechanisms of action, and future directions for improving patient outcomes.</div></div>","PeriodicalId":51185,"journal":{"name":"Surgical Oncology-Oxford","volume":"57 ","pages":"Article 102160"},"PeriodicalIF":2.3,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142696180","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Melanoma sentinel lymph node biopsy in the modern era","authors":"Teodora Dumitra ,&nbsp;Mark B. Faries","doi":"10.1016/j.suronc.2024.102162","DOIUrl":"10.1016/j.suronc.2024.102162","url":null,"abstract":"<div><div>The initial route of metastasis for many cancers, including melanoma, is via regional lymphatic channels. This fact, recognized more than a century ago, has spurred tremendous interest in the optimal method of assessing and treating lymph nodes and eventually led to the development of lymphatic mapping and sentinel lymph node (SLN) biopsy. The potential utility of nodal treatment includes providing the most accurate staging or prognostic information and removing early metastases in order to halt the cascade of metastatic spread in an effort to save the patient's life. In the past, pathologic assessment of regional lymph nodes required removal of all regional nodes, a procedure that results in moderate levels of short and long-term morbidity. SLN biopsy allows not only a minimally invasive method of nodal assessment, but one more accurate than full node dissection as it permits more intensive pathologic scrutiny of the tissue. The question of the therapeutic effect of SLN biopsy has been a subject of much controversy. There is clear evidence that SLN biopsy improves relapse-free survival in melanoma, but its effect on melanoma-specific and overall survival remains less clear.</div></div>","PeriodicalId":51185,"journal":{"name":"Surgical Oncology-Oxford","volume":"57 ","pages":"Article 102162"},"PeriodicalIF":2.3,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142655864","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bilobed lateral artery perforator-based flap for partial breast reconstruction – Technique description and results from a ten-year cohort","authors":"Regis R. Paulinelli ,&nbsp;Ana F.F. Goulart ,&nbsp;Horacio Mendoza Santos ,&nbsp;Barbara A. Barbosa ,&nbsp;Ana-Luisa F. Silva ,&nbsp;Luiz-Fernando J. Ribeiro ,&nbsp;Ruffo Freitas-Junior","doi":"10.1016/j.suronc.2024.102161","DOIUrl":"10.1016/j.suronc.2024.102161","url":null,"abstract":"<div><h3>Introduction</h3><div>We present a new technique, the bilobed lateral artery perforator-based flap, for breast-conserving surgery of large central tumors or nearby, combining Zymany's bilobed flap and a Lateral Intercostal Perforator (LICAP) flap, and its 10-year outcomes.</div></div><div><h3>Materials and methods</h3><div>We studied 37 patients with malignant breast tumors near or involving the central skin, without ptosis or desire to correct it, who avoided mastectomy with this modified bilobed flap from 2013 to 2022. The same surgeon operated on them in different institutions. This research project was approved by our ethical committee (n. 2.322.212).</div></div><div><h3>Results</h3><div>The mean age was 57.17 (±12.60) years. The mean specimen weight was 74.32 (±25.84)g, and the mean tumor size was 40.35 (±15.81) mm. Fourteen (37.84 %) tumors were larger than 5 cm and one was multicentric. Thirty-two (86.49 %) patients had invasive ductal carcinomas. Nipple areola complex was removed in 19 (51.35 %) cases due to clinical involvement, and immediately reconstructed in two cases with contralateral free grafting. Twenty-one (56.76 %) patients received neoadjuvant chemotherapy. Three (8.11 %) patients had immediate contralateral mastopexy. Radiotherapy was indicated in all cases. There were 3 (8.11 %) minor complications, one positive margin, and no surgical revisions. In a mean follow-up of 39.97 (±29.43) months, there were no local recurrences, 2 metastasis, and one death. Satisfaction and aesthetic results were good or excellent in most cases.</div></div><div><h3>Conclusions</h3><div>The new technique enabled breast conservation, with high rates of free margins, high levels of satisfaction, few complications in women with large central tumors on small breasts with limited ptosis.</div></div>","PeriodicalId":51185,"journal":{"name":"Surgical Oncology-Oxford","volume":"57 ","pages":"Article 102161"},"PeriodicalIF":2.3,"publicationDate":"2024-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142631597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Individualizing care for patients with gallbladder cancer","authors":"Laura M. Nicolais ,&nbsp;Timothy L. Fitzgerald","doi":"10.1016/j.suronc.2024.102163","DOIUrl":"10.1016/j.suronc.2024.102163","url":null,"abstract":"<div><div>The rarity and lack of Level I Evidence compromise our ability to care for patients with gallbladder cancer.</div></div><div><h3>Methods</h3><div>NCDB cohort study of with resected Stage Groups IB-IVA gallbladder adenocarcinoma between 2004 and 2018. Patients were included.</div></div><div><h3>Results</h3><div>8484 patients were included, median survival was 29.8 (CI 28.6–31.2); Stage IB: 67.0, Stage II: 36.6, and Stage III/IVA 18.4 months. A survival benefit was noted for surgery beyond cholecystectomy (Stage IB 105 vs. 36 months, HR 0.56, p &lt; 0.001; Stage II 56 vs. 20 months, HR 0.72, p &lt; 0.001; and Stage III/IVA 23.8 vs. 9.9 months, HR 0.67, p &lt; 0.001) and chemoradiotherapy (Stage IB 102 vs. 64.8, HR 0.87, CI 0.62–1.23, p = 0.4; ' Stage II 49 vs. 33.5 months, HR 0.78, CI 0.68–0.91, p = 0.002; and Stage III/IVA 31 vs. 12.2 HR 0.60, CI 0.52–0.70, p &lt; 0.001). Adjuvant chemotherapy improved survival in Stage III/IVA (20 vs. 12.2 months, HR 0.74, p &lt; 0.001) but not Stage II and trend toward harm in Stage IB. A nomogram with created with these data.</div></div><div><h3>Conclusion</h3><div>Surgery beyond cholecystectomy provides a benefit to all. Adjuvant chemotherapy (Stage III and IVA) benefits and chemoradiotherapy (II, III, and IVA) only patients with higher stage disease.</div></div>","PeriodicalId":51185,"journal":{"name":"Surgical Oncology-Oxford","volume":"57 ","pages":"Article 102163"},"PeriodicalIF":2.3,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142578630","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Natural history of salivary gland secretory carcinoma: A REFCOR study.","authors":"Marie Magana ,&nbsp;Sebastien Vergez ,&nbsp;Benjamin Verillaud ,&nbsp;Renaud Garrel ,&nbsp;Diane Evrard ,&nbsp;François Mouawad ,&nbsp;Ludovic de Gabory ,&nbsp;Nicolas Fakhry ,&nbsp;Franck Jegoux ,&nbsp;Olivier Malard ,&nbsp;Christine Bach ,&nbsp;Pierre Philouze ,&nbsp;Karine Aubry ,&nbsp;Olivier Mauvais ,&nbsp;Antoine Moya Plana ,&nbsp;Jean Paul Marie ,&nbsp;Bertrand Baujat ,&nbsp;Sarah Atallah","doi":"10.1016/j.suronc.2024.102159","DOIUrl":"10.1016/j.suronc.2024.102159","url":null,"abstract":"<div><h3>Background and objectives</h3><div>Salivary gland Secretory Carcinoma (SC), characterized by Skalova in 2010 is a rare tumor studied within the REFCOR (French Network of experts on Rare Head and Neck Cancers). We conducted a prospective multicentric cohort study of 108 SC cases in the REFCOR database up to July 2021, analyzing diagnostic, therapeutic, and survival data.</div></div><div><h3>Methods</h3><div><em>Data was</em> collected prospectively from diagnosis to the last update. Each patient had two histological readings including one by a REFCORpath pathologist, and all cases underwent molecular testing to confirm diagnosis. Statistical analyses were performed using R software.</div></div><div><h3>Results</h3><div>MRI was not contributive to malignancy diagnosis. After 2 histological readings, 79 % of patients were diagnosed, with 21 % requiring molecular testing to confirm diagnosis. Surgical treatment typically involved tumor excision and lymph node dissection. The tumor exhibited low lymph node involvement, with 95 % of patients being cN0, and no nodal metastases post-dissection. Five-year overall survival and recurrence-free survival were 91.4 % {95 % CI (0.84–1)} and 89 % {95 % CI (0.81; 0.98)} respectively, indicating a favorable prognosis.</div></div><div><h3>Conclusions</h3><div>SC is a rare and newly recognized tumor, with generally favorable outcomes. Our cohort, among the largest to date, provides valuable insights. Future research should refine treatment guidelines.</div></div>","PeriodicalId":51185,"journal":{"name":"Surgical Oncology-Oxford","volume":"57 ","pages":"Article 102159"},"PeriodicalIF":2.3,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142561209","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tumor necrosis drives prognosis in osteosarcoma: No difference in chemotherapy response and survival between chondroblastic and osteoblastic osteosarcoma","authors":"Neel Patel ,&nbsp;Joseph O. Werenski ,&nbsp;Marcos R. Gonzalez ,&nbsp;Marilee J. Clunk ,&nbsp;Meagan R. McCadden ,&nbsp;Alexis Richard ,&nbsp;Ivan Chebib ,&nbsp;Yin P. Hung ,&nbsp;G. Petur Nielsen ,&nbsp;Santiago A. Lozano-Calderon","doi":"10.1016/j.suronc.2024.102155","DOIUrl":"10.1016/j.suronc.2024.102155","url":null,"abstract":"<div><h3>Introduction</h3><div>The percentage of tumor necrosis is a crucial prognostic factor in osteosarcoma. Many studies adopt a 90 % cutoff based on osteoblastic osteosarcoma, but these findings are generalized to all conventional subtypes, including chondroblastic osteosarcoma. We sought to answer these questions: (1) Is tumor necrosis ≥90 % associated with better overall survival (OS) and disease-free survival (DFS) in osteoblastic and chondroblastic osteosarcoma? (2) Does the osteosarcoma subtype impact tumor necrosis? (3) Does the osteosarcoma subtype in “good” responders (tumor necrosis ≥90 %) affect OS and DFS?.</div></div><div><h3>Materials and methods</h3><div>We conducted a retrospective study of 156 patients with osteoblastic and chondroblastic osteosarcoma treated at our institution. All patients received a standardized chemotherapy protocol and underwent surgery with the goal of achieving negative margins (R0 resection). Propensity-score matching was performed to adjust for potential confounders. Kaplan-Meier survival analysis and Cox proportional hazards modeling were performed.</div></div><div><h3>Results</h3><div>Patients with osteoblastic osteosarcoma and tumor necrosis ≥90 % had higher 5- and 10-year OS and DFS compared to those with necrosis &lt;90 %. In chondroblastic osteosarcoma, a trend towards higher OS and DFS was seen in patients with tumor necrosis ≥90 %; this, however, was not significant. Chondroblastic osteosarcoma was not a risk factor for either tumor necrosis &lt;90 % (p = 0.89) or tumor necrosis &lt;70 % (p = 0.57). Patients with osteoblastic or chondroblastic osteosarcoma that were deemed “good” responders (tumor necrosis ≥90 %) had similar OS and DFS at the 5- and 10-year marks.</div></div><div><h3>Conclusion</h3><div>Conventional osteosarcoma subtype was not a risk factor for “poor” response<strong>.</strong> Survival outcomes (OS and DFS) were similar for osteoblastic and chondroblastic osteosarcoma with good response to chemotherapy.</div></div>","PeriodicalId":51185,"journal":{"name":"Surgical Oncology-Oxford","volume":"57 ","pages":"Article 102155"},"PeriodicalIF":2.3,"publicationDate":"2024-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142445297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}